Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and ...
Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma Posters also feature data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback